Dog Congenital Myasthenic Syndrome In Heideterrier (CMS-H)

Discover the importance of the DNA test for Congenital Myasthenic Syndrome (CMS) in Heideterriers, a hereditary neuromuscular disorder affecting this unique dog breed. Early genetic screening helps breeders identify carriers and prevent the transmission of CMS, ensuring healthier litters. This precise DNA test detects mutations linked to CMS, allowing for informed breeding decisions and improved canine health. Regular testing supports responsible breeding practices and enhances the overall well-being of Heideterriers. Protect your dog’s future by choosing reliable CMS DNA testing today. Stay proactive in managing congenital health risks with advanced genetic tools.

Abbreviation : CMS-H

Analysed mutation : CHRNE c.1436_1437insG

Inheritance : Autosomal Recessive

Acronym

CMS-H

Observed frequency

Rare

Clinical severity

Moderate

Clinical classification

Neuromuscular Diseases

Analysed mutation

CHRNE c.1436_1437insG
p.(S503Rfs*14)

Mode of inheritance

Autosomal Recessive

Test summary:

The DNA test for Congenital Myasthenic Syndrome (CMS) in Heideterriers helps identify genetic mutations responsible for this inherited neuromuscular disorder. CMS causes muscle weakness and fatigue due to impaired nerve-to-muscle communication. Early detection through genetic testing enables breeders to make informed decisions and reduce the risk of passing the condition to offspring. This test is essential for maintaining the health and vitality of the Heideterrier breed. Regular screening supports responsible breeding and improves overall canine welfare.

Available from the pack : Basic

This DNA test is included starting from our pack Basic — and is also part of the packs Basic, Standard, Advanced, Complete.

View DNA Test Packs →

Choose the pack that best fits your breeding or health strategy of your animals.

Overview of Congenital Myasthenic Syndrome (CMS)

Congenital Myasthenic Syndrome (CMS) is a group of inherited neuromuscular disorders characterized by weakness and fatigue of voluntary muscles. This condition results from defects in the transmission of nerve impulses to muscles, leading to compromised muscle function. It is caused by genetic mutations that affect the proteins responsible for neuromuscular transmission, notably at the neuromuscular junction where nerve cells communicate with muscles.

Symptoms of CMS in Dogs

Dogs affected by CMS may exhibit a range of symptoms, including muscle weakness, exercise intolerance, and fatigue. Some dogs may also show signs of difficulty in swallowing, facial muscle weakness, and a tendency to collapse after exertion. These symptoms can vary in severity and may be mistaken for other conditions, making a proper diagnosis crucial for effective management.

Importance of DNA Testing for CMS

DNA testing plays a vital role in identifying genetic mutations associated with Congenital Myasthenic Syndrome. By analyzing specific genes known to be linked to CMS, veterinarians and breeders can better understand the genetic predisposition of individual dogs. This information is crucial for making informed breeding decisions and helps in managing the condition in affected dogs.

Management and Treatment Options

Currently, there is no cure for Congenital Myasthenic Syndrome; however, management strategies are available to improve the quality of life for affected dogs. Treatment often includes the use of medications such as anticholinesterase agents, which can enhance neuromuscular transmission. Supportive care, including physical therapy and nutritional management, is also essential to help maintain muscle function and overall health.

Conclusion

Congenital Myasthenic Syndrome is a serious condition that can significantly affect the life of a dog. Early diagnosis through DNA testing can facilitate proper management and care, ensuring that affected dogs receive the support they need to lead a fulfilling life. Understanding the implications of this condition is vital for dog owners, breeders, and veterinary professionals alike.

Breed recognized for the test : Congenital Myasthenic Syndrome In Heideterrier (CMS-H)

Heideterrier
Smooth Fox Terrier

Interpretation of genotypes Genotype Status Learn more about the interpretation of genotypes FAQ: understanding the interpretation of result What does “Clear” mean? The animal does not carry the mutation. It will not develop the disease and will not pass it on. Is a “Carrier” serious? No. The animal is generally healthy but can transmit the mutation to its offspring. What if an animal is “Affected”? It carries two mutated copies. Clinical signs are expected depending on the disease. It should not be bred. Why are there differences between male / female? Some diseases are sex-linked, so their expression varies depending on the animal’s sex. The animal has two normal copies of the gene. No risk of developing or transmitting the disease. Heterozygous carrier: one mutated copy. The animal is usually not clinically affected but can pass the mutation to offspring. Male carrier or affected depending on the inheritance mode. Males have only one X or Y chromosome. Heterozygous female carrier: one mutated copy. She can pass the mutation on and may sometimes show mild clinical signs depending on the condition. Two mutated copies of the gene. The animal is at risk of developing the associated condition.

🧬 Interpretation of genotypes CMS-H

Genotype

Status

🟡 N/N

Non-carrier - No Risk

🟡 N/CMS-H

Carrier - No Risk

❌ CMS-H/CMS-H

Affected - At Risk

FAQ: understanding the interpretation

What does “Clear” mean?

The animal does not carry the mutation. It will not develop the disease and will not pass it on.

Is a “Carrier” serious?

No. The animal is generally healthy but can transmit the mutation to its offspring.

What if an animal is “Affected”?

It carries two mutated copies. Clinical signs are expected depending on the disease. It should not be bred.

Why are there differences between male / female?

Some diseases are sex-linked, so their expression varies depending on the animal’s sex.

Genotype Forecast for Offspring Mother Father Non-carrier Carrier Affected Favorable cross: majority Carrier risk is predominant. Majority affected Filter by mother's genotype Filter by father's genotype All Predict Offspring The animal has two normal copies of the gene. No risk of developing or transmitting the disease. Heterozygous carrier: one mutated copy. The animal is usually not clinically affected but can pass the mutation to offspring. Male carrier or affected depending on the inheritance mode. Males have only one X or Y chromosome. Heterozygous female carrier: one mutated copy. She can pass the mutation on and may sometimes show mild clinical signs depending on the condition. Two mutated copies of the gene. The animal is at risk of developing the associated condition.

Predict Offspring

Filter by mother's genotype Filter by father's genotype

N/N (Non-carrier)

N/CMS-H (Carrier)

CMS-H/CMS-H (Affected)

DNA Test FAQ

What does this DNA test detect?

This DNA test detects the mutation associated with Congenital Myasthenic Syndrome In Heideterrier (CMS-H) in order to identify clear, carrier, or at-risk animals.

Why test a breeding animal?

DNA testing helps breeders plan safer matings and reduce the risk of transmitting the mutation to offspring.

What is the inheritance mode of this test?

The inheritance mode reported for this test is Autosomal Recessive.

Which mutation is analysed in this test?

This test analyses the mutation CHRNE c.1436_1437insG.

Is a carrier animal necessarily affected?

Not necessarily. Interpretation depends on the inheritance pattern and the resulting genotype.

References

Herder Vanessa, Ciurkiewicz Malgorzata, Baumgärtner Wolfgang, Jagannathan Vidhya, Leeb Tosso. Frame-shift variant in the CHRNE gene in a juvenile dog with suspected myasthenia gravis-like disease. Anim Genet. 2017 Oct;48(5):625. doi: 10.1111/age.12558. Epub 2017 May 16.

My DNA Portal